De novo induction of antigen‐specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR

Although regulatory CD4+CD25+ forkhead box p3+ (Foxp3+) T cells (Tregs) are generally thought to arise in the thymus as a separate lineage of CD4 T cells, they can also be induced de novo in the periphery. Peripheral development of Tregs from naïve T cells is favored by low‐intensity activation and absence of inflammation. We show here that absence of CD28 costimulation results in a modest decrease in activation of naïve, antigen‐specific CD4 T cells under noninflammatory conditions and benefits their initial Foxp3 induction. However, expression of Foxp3 following T cell activation without CD28 costimulation remains sensitive to the antigen dose. Furthermore, basal CD28 costimulation is critical for survival of the induced Foxp3+ CD4 T cells, and their accumulation is abrogated in the absence of CD28. In contrast, pharmacologic blockade of mammalian target of rapamycin enhances lasting induction of Tregs, irrespective of the initial antigen dose used to activate the antigen‐specific T cells. This finding may have important practical, clinical implication in development of tolerance protocols.

[1]  R. Negrin,et al.  Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. , 2008, Blood.

[2]  Wenda Gao,et al.  Reciprocal generation of Th1/Th17 and Treg cells by B1 and B2 B cells , 2007, European journal of immunology.

[3]  D. Fuchs,et al.  Regulatory T-Cell Markers, Indoleamine 2,3-Dioxygenase, and Virus Levels in Spleen and Gut during Progressive Simian Immunodeficiency Virus Infection , 2007, Journal of Virology.

[4]  A. Mondino,et al.  mTOR at the crossroads of T cell proliferation and tolerance. , 2007, Seminars in immunology.

[5]  W. Sandborn,et al.  Inflammatory bowel disease: clinical aspects and established and evolving therapies , 2007, The Lancet.

[6]  A. Rudensky,et al.  Foxp3 in control of the regulatory T cell lineage , 2007, Nature Immunology.

[7]  L. Boon,et al.  Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+CD25+FoxP3+ T cells , 2007, Bone Marrow Transplantation.

[8]  Tianfu Wu,et al.  PI3K/AKT/mTOR hypersignaling in autoimmune lymphoproliferative disease engendered by the epistatic interplay of Sle1b and FASlpr. , 2007, International immunology.

[9]  V. Kuchroo,et al.  Contrasting Effects of Cyclosporine and Rapamycin in De Novo Generation of Alloantigen‐Specific Regulatory T Cells , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  M. Baccarani,et al.  Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. , 2007, Blood.

[11]  T. Whiteside,et al.  Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin1 , 2007, The Journal of Immunology.

[12]  M. Farrar,et al.  IL-2 Receptor β-Dependent STAT5 Activation Is Required for the Development of Foxp3+ Regulatory T Cells1 , 2007, The Journal of Immunology.

[13]  R. Truitt,et al.  Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. , 2007, Cytotherapy.

[14]  M. Battaglia,et al.  Rapamycin Promotes Expansion of Functional CD4+CD25+FOXP3+ Regulatory T Cells of Both Healthy Subjects and Type 1 Diabetic Patients1 , 2006, The Journal of Immunology.

[15]  U. Grohmann,et al.  Tryptophan catabolism generates autoimmune-preventive regulatory T cells. , 2006, Transplant immunology.

[16]  C. Chougnet,et al.  HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. , 2006, Blood.

[17]  Shile Huang,et al.  Predicted mechanisms of resistance to mTOR inhibitors , 2006, British Journal of Cancer.

[18]  M. Arias,et al.  Calcineurin Inhibitors, but not Rapamycin, Reduce Percentages of CD4+CD25+FOXP3+ Regulatory T Cells in Renal Transplant Recipients , 2006, Transplantation.

[19]  L. Ignatowicz,et al.  Origin and T cell receptor diversity of Foxp3+CD4+CD25+ T cells. , 2006, Immunity.

[20]  C. Chougnet,et al.  Do regulatory T-cells play a role in AIDS pathogenesis? , 2006, AIDS reviews.

[21]  B. Kyewski,et al.  Foxp3+ CD25+ regulatory T cells specific for a neo-self-antigen develop at the double-positive thymic stage. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Sadelain,et al.  Cutting Edge: CD28 Controls Dominant Regulatory T Cell Activity during Active Immunization1 , 2006, The Journal of Immunology.

[23]  V. Basso,et al.  Prolonged TCR/CD28 Engagement Drives IL-2-Independent T Cell Clonal Expansion through Signaling Mediated by the Mammalian Target of Rapamycin1 , 2006, The Journal of Immunology.

[24]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[25]  P. Moingeon,et al.  Immune mechanisms of allergen‐specific sublingual immunotherapy , 2006, Allergy.

[26]  H. Koenen,et al.  Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. , 2006, Blood.

[27]  M. Nussenzweig,et al.  Inducing and expanding regulatory T cell populations by foreign antigen , 2005, Nature Immunology.

[28]  A. Rudensky,et al.  Developmental regulation of Foxp3 expression during ontogeny , 2005, The Journal of experimental medicine.

[29]  R. Lahesmaa,et al.  Expression of human pim family genes is selectively up‐regulated by cytokines promoting T helper type 1, but not T helper type 2, cell differentiation , 2005, Immunology.

[30]  M. Battaglia,et al.  Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. , 2005, Blood.

[31]  B. Baban,et al.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. , 2005, Immunity.

[32]  A. Khoruts,et al.  A model of suppression of the antigen-specific CD4 T cell response by regulatory CD25+CD4 T cells in vivo. , 2005, International immunology.

[33]  P. Hammerman,et al.  The Pim kinases control rapamycin-resistant T cell survival and activation , 2005, The Journal of experimental medicine.

[34]  A. Singer,et al.  CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2 , 2005, Nature Immunology.

[35]  A. Khoruts,et al.  A Role for CD28 in Lymphopenia-Induced Proliferation of CD4 T Cells1 , 2004, The Journal of Immunology.

[36]  H. von Boehmer,et al.  In Vivo Instruction of Suppressor Commitment in Naive T Cells , 2004, The Journal of experimental medicine.

[37]  D. Munn,et al.  Ligation of B7-1/B7-2 by Human CD4+ T Cells Triggers Indoleamine 2,3-Dioxygenase Activity in Dendritic Cells1 , 2004, The Journal of Immunology.

[38]  M. Dougados,et al.  Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. , 2003, The New England journal of medicine.

[39]  E. Ingulli,et al.  Development of a Novel Transgenic Mouse for the Study of Interactions Between CD4 and CD8 T Cells During Graft Rejection , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[40]  U. Grohmann,et al.  Modulation of tryptophan catabolism by regulatory T cells , 2003, Nature Immunology.

[41]  J. Bluestone,et al.  Cutting Edge: CD28 Controls Peripheral Homeostasis of CD4+CD25+ Regulatory T Cells 1 , 2003, The Journal of Immunology.

[42]  J. Lohr,et al.  The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens , 2003, Nature Immunology.

[43]  F. Ramsdell,et al.  An essential role for Scurfin in CD4+CD25+ T regulatory cells , 2003, Nature Immunology.

[44]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[45]  A. Khoruts,et al.  Competition for self ligands restrains homeostatic proliferation of naive CD4 T cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[47]  U. Grohmann,et al.  CTLA-4–Ig regulates tryptophan catabolism in vivo , 2002, Nature Immunology.

[48]  M. Jenkins,et al.  Flow Cytometric Analysis of T Cell Receptor Signal Transduction , 2002, Science's STKE.

[49]  A. Khoruts,et al.  Antagonistic Roles for CTLA-4 and the Mammalian Target of Rapamycin in the Regulation of Clonal Anergy: Enhanced Cell Cycle Progression Promotes Recall Antigen Responsiveness1 , 2001, The Journal of Immunology.

[50]  T. Laufer,et al.  Major Histocompatibility Complex Class II–Positive Cortical Epithelium Mediates the Selection of Cd4+25+ Immunoregulatory T Cells , 2001, The Journal of experimental medicine.

[51]  A. Khoruts,et al.  Generation of Anergic and Potentially Immunoregulatory CD25+CD4 T Cells In Vivo After Induction of Peripheral Tolerance with Intravenous or Oral Antigen1 , 2001, The Journal of Immunology.

[52]  A. Gingras,et al.  Regulation of translation initiation by FRAP/mTOR. , 2001, Genes & development.

[53]  A. Naji,et al.  Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide , 2001, Nature Immunology.

[54]  J. Bluestone,et al.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. , 2000, Immunity.

[55]  B. Nelson,et al.  The IL-2 Receptor Promotes Lymphocyte Proliferation and Induction of the c-myc, bcl-2, and bcl-x Genes Through the trans-Activation Domain of Stat51 , 2000, The Journal of Immunology.

[56]  H. Lodish,et al.  Fetal Anemia and Apoptosis of Red Cell Progenitors in Stat5a−/−5b−/− Mice A Direct Role for Stat5 in Bcl-XL Induction , 1999, Cell.

[57]  F. Otsuka,et al.  Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. , 1999, Journal of immunology.

[58]  B. Blazar,et al.  Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. , 1998, Journal of immunology.

[59]  A. Khoruts,et al.  A Natural Immunological Adjuvant Enhances T Cell Clonal Expansion through a CD28-dependent, Interleukin (IL)-2–independent Mechanism , 1998, The Journal of experimental medicine.

[60]  H. Rui,et al.  Two Discrete Regions of Interleukin-2 (IL2) Receptor β Independently Mediate IL2 Activation of a PD98059/Rapamycin/Wortmannin-insensitive Stat5a/b Serine Kinase* , 1997, The Journal of Biological Chemistry.

[61]  T. Strom,et al.  Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. , 1997, Immunity.

[62]  A. B. Lyons,et al.  Determination of lymphocyte division by flow cytometry. , 1994, Journal of immunological methods.